IFITM3 and severe influenza virus infection. No evidence of genetic association.

Autor: López-Rodríguez M; Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, 35010, Spain.; Department of Clinical Sciences, School of Medicine, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, 35016, Spain., Herrera-Ramos E; Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, 35010, Spain.; Department of Medical and Surgical Sciences, School of Medicine, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, 35016, Spain., Solé-Violán J; Intensive Care Unit, Hospital Universitario de Gran Canaria Dr. Negrín, CIBERES, Las Palmas de Gran Canaria, 35010, Spain., Ruíz-Hernández JJ; Department of Internal Medicine, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas Gran Canaria, 35010, Spain., Borderías L; Department of Respiratory Diseases, Hospital San Jorge, Huesca, 22004, Spain., Horcajada JP; Department of Infectious Diseases, Hospital Universitari del Mar, Barcelona, 08003, Spain.; Hospital del Mar de Investigaciones Médicas (IMIM), CIBERES, Barcelona, 08003, Spain., Lerma-Chippirraz E; Department of Infectious Diseases, Hospital Universitari del Mar, Barcelona, 08003, Spain., Rajas O; Department of Respiratory Diseases, Hospital Universitario de la Princesa, Madrid, 28005, Spain., Briones M; Department of Respiratory Diseases, Hospital Clínico y Universitario de Valencia, Valencia, 46010, Spain., Pérez-González MC; Department of Microbiology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, 35010, Spain., García-Bello MA; Department of Statistics, Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, 35010, Spain., López-Granados E; Department of Immunology, Hospital La Paz, La Paz Institute of Biomedical Research, IdiPAZ, Madrid, 28046, Spain., Rodriguez de Castro F; Department of Medical and Surgical Sciences, School of Medicine, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, 35016, Spain.; Department of Respiratory Diseases, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, 35010, Spain., Rodríguez-Gallego C; Department of Immunology, Hospital Universitario Son Espases, Palma de Mallorca, 07120, Spain. josecarlos.rodriguezgallego@ssib.es.; Department of Immunology, Hospital Universitario Son Espases, Carretera de Valldemossa 79, 07120, Palma de Mallorca, Spain. josecarlos.rodriguezgallego@ssib.es.
Jazyk: angličtina
Zdroj: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology [Eur J Clin Microbiol Infect Dis] 2016 Nov; Vol. 35 (11), pp. 1811-1817. Date of Electronic Publication: 2016 Aug 04.
DOI: 10.1007/s10096-016-2732-7
Abstrakt: Influenza virus infection (IVI) is typically subclinical or causes a self-limiting upper respiratory disease. However, in a small subset of patients IVI rapidly progresses to primary viral pneumonia (PVP) with respiratory failure; a minority of patients require intensive care unit admission. Inherited and acquired variability in host immune responses may influence susceptibility and outcome of IVI. However, the molecular basis of such human factors remains largely elusive. It has been proposed that homozygosity for IFITM3 rs12252-C is associated with a population-attributable risk of 5.4 % for severe IVI in Northern Europeans and 54.3 % for severe H1N1pdm infection in Chinese. A total of 148 patients with confirmed IVI were considered for recruitment; 118 Spanish patients (60 of them hospitalized with PVP) and 246 healthy Spanish individuals were finally included in the statistical analysis. PCR-RFLP was used with confirmation by Sanger sequencing. The allele frequency for rs12252-C was found to be 3.5 % among the general Spanish population. We found no rs12252-C homozygous individuals in our control group. The only Spanish patient homozygous for rs12252-C had a neurological disorder (a known risk factor for severe IVI) and mild influenza. Our data do not suggest a role of rs12252-C in the development of severe IVI in our population. These data may be relevant to recognize whether patients homozygous for rs12252-C are at risk of severe influenza, and hence require individualized measures in the case of IVI.
Databáze: MEDLINE
Externí odkaz: